Elevance Health (ELV) Stock Still Looks Reasonable Despite Its 12% Gain

Simply Wall St.10-03

Elevance Health has delivered a 12.4% gain over the past year, even as shorter term moves have been choppy, and that raises a simple question for you as an investor. Is the current share price of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2672723902?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/160077-card/1789190616038","is_english":true,"pubTime":"2026-10-03 18:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672723902","market":"nz","top_or_hot":-1,"title":"Elevance Health (ELV) Stock Still Looks Reasonable Despite Its 12% Gain","media":"Simply Wall St.","content":"<div>\n<p>Elevance Health has delivered a 12.4% gain over the past year, even as shorter term moves have been choppy, and that raises a simple question for you as an investor. Is the current share price of the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-stock-still-looks-reasonable-despite-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elevance Health (ELV) Stock Still Looks Reasonable Despite Its 12% Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElevance Health (ELV) Stock Still Looks Reasonable Despite Its 12% Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-03 18:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-stock-still-looks-reasonable-despite-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elevance Health has delivered a 12.4% gain over the past year, even as shorter term moves have been choppy, and that raises a simple question for you as an investor. Is the current share price of the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-stock-still-looks-reasonable-despite-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2505996681.GBP","symbol_name":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-stock-still-looks-reasonable-despite-its","article_id":"2672723902","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/160077-card/1789190616038"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-stock-still-looks-reasonable-despite-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672723902","pubTimestamp":1791022583,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Elevance Health has delivered a 12.4% gain over the past year, even as shorter term moves have been choppy, and that raises a simple question for you as an investor. Is the current share price of the health benefits group adequately grounded in the earnings that support it, or has sentiment moved ahead of the underlying profit stream?\n\nThe 12.4% return over the past year puts real weight on whether Elevance Health’s current earnings power can sustain that kind of shareholder experience.\nThe...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","SG9999001077.SGD":"United International Growth Fund SGD","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","LU0251142724.SGD":"Fidelity America A-SGD","ELV":"Elevance Health","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0061474960.USD":"天利环球焦点基金AU Acc","RGLO":"Global Equity Active ETF","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","VGFPF":"Vanguard Funds PLC","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","BK7095":"多种金属与采矿","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","GXDW":"Global X Dorsey Wright Thematic ETF","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0882574055.USD":"富达全球健康医疗A ACC","ELV.AU":"ELEVRA LITHIUM LTD","PMDE":"PGIM S&P 500 Max Buffer ETF - December","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4588":"碎股","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","VOTE":"TCW Transform 500 ETF","BK4154":"管理型保健护理","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"尽管上涨了 12%，Elevance Health (ELV) 股票看起来仍然合理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOTE":0.9,"ELV":1.5,"FEBU":0.9,"GXDW":0.9,"RGLO":0.9,"ELV.AU":1.5,"DECU":0.9,"JOYT":0.9,"VGFPF":0.9,"PMDE":0.9},"content_text":"Elevance Health has delivered a 12.4% gain over the past year, even as shorter term moves have been choppy, and that raises a simple question for you as an investor. Is the current share price of the health benefits group adequately grounded in the earnings that support it, or has sentiment moved ahead of the underlying profit stream?  The 12.4% return over the past year puts real weight on whether Elevance Health’s current earnings power can sustain that kind of shareholder experience. The company’s push to expand and refine its Medicare Advantage offerings, including more tailored plans for complex members, can influence future profitability by shifting the mix of earnings, the stability of cash flows, and the level of required investment. The analysts covering Elevance Health have run their own numbers. See what analysts think Elevance Health's shares could be worth.  The stock’s next move may depend on whether Elevance Health’s current earnings profile is strong enough to justify where the shares trade today. If you want to test the same earnings question you are asking of Elevance Health across a broader group of stocks with similar traits, take a look at solid balance sheet and fundamentals stocks screener (26 results). AdvertisementIs Elevance Health Still Cheap on Earnings? The P/E ratio suits Elevance Health because earnings still sit at the center of how investors judge large, established insurers. On that measure, Elevance Health trades on about 16.9x earnings, compared with roughly 24.3x for the wider healthcare group and about 26.3x for peers in its comparison set. That is a sizable gap for a major managed care business where profits, not sales hype, tend to drive long term returns. Because the modeled \"fair\" P/E for Elevance Health, which blends in its growth profile, margins, scale and risk, sits above the current multiple, the shares screen as undervalued on this framework. Despite the recent focus on expanded Medicare Advantage offerings for 2027, the current P/E still prices Elevance Health at a discount to both the sector and similar stocks, which suggests sentiment has not chased the story too far. Explore the numbers behind Elevance Health's P/E valuation. NYSE:ELV P/E Ratio as at Oct 2026 The Elevance Health Narrative: What Would Justify Today's Price? Narratives on Elevance Health act as the missing link between the current P/E puzzle and the assumptions that would need to hold on growth, margins and earnings for the stock to be worth materially more or less than today’s price. They sit on Simply Wall St’s Community page. Each scenario ties a fair value estimate to a clear storyline about Elevance Health's potential catalysts and key risks so you can see over time which version of events is actually taking shape. One of the top community narratives on Elevance Health: 14% undervalued \"Ongoing deployment of Elevance Health’s AI, analytics and digital platforms such as HealthOS and Sydney Health, including automated prior authorization and earlier visibility into medical cost trends…\" Discover why this Narrative puts Elevance Health at 14% undervalued. One more Elevance Health question that current valuation alone cannot answer Price multiples tell you what Elevance Health is worth today, but broker models sketch where earnings and cash generation might go over the next few years, and how that lines up with this market tag. Explore where analysts expect Elevance Health to be in a few years.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2672723902","isCrawlerRequest":true}